Dr. Steven A. Silber is a physician, pharmaceutical executive, and consultant with more than four decades of experience across academic medicine, biotechnology, and global pharmaceutical leadership. He is recognized for his expertise in drug development, regulatory strategy, and global health, and serves actively in board leadership roles in the life sciences and nonprofit sectors.

Dr. Silber currently serves on the Boards of Directors of the Beyond Batten Disease Foundation and the Elwyn Foundation. He was previously Board Chair of Together Strong NPC, where he led governance and strategic growth to support research in Niemann-Pick Type C disease.

Over his executive career, Dr. Silber held senior leadership positions at Johnson & Johnson, including Vice President of Drug Development & Safety, Vice President of Established Products, and Medical Advisor in Global Public Health. He also led a biotechnology start-up as Chief Executive Officer of CryBiomedicines, LLC, and currently advises clients as a consultant with NGT BioPharma Consultants.

Earlier in his career, Dr. Silber served as Director of the Internal Medicine Residency Program and Assistant Professor at the University of Pennsylvania Health System, where he trained the next generation of physicians and advanced clinical research programs.

Through his combination of medical expertise, executive leadership, and board governance, Dr. Silber brings a unique perspective to organizations navigating the evolving landscape of healthcare, biotechnology, and global health.

Select Publications:

• Silber, SA, Diro, E, Workneh, N et al. Efficacy and safety of a sing-dose mebendazole 500mg chewable, rapidly-disintegrating tablet for Ascaris lumbridoides and Trichuris trichiura infection treatment in pediatric patients: A double-blind, randomized, placebo-controlled, phase 3 study.     American Journal of Tropical Medicine and Hygiene (In press)
• Mrus J, Baeten B, Engelen M, Silber SA. Efficacy of single-dose 500 mg mebendazole in soil-transmitted helminth infections: a review. J Helminthol. 2017 Jul 18:1-10.
• Lagatie O, Njumbe Ediage E, Batsa Debrah L, Diels L, Nolten C, Vinken P, Debrah A, Dillen L, Silber S, Stuyver LJ. Evaluation of the diagnostic potential of urinary N-Acetyltyramine-O, β-glucuronide (NATOG) as diagnostic biomarker for Onchocerca volvulus infection. Parasit Vectors. 2016 May 23; 9 (1):302.
• Flubendazole, A potential useful chemotherapeutic agent for the treatment and control of filarial infections. Mackenzie CD, Specht S, Geary T, O’Neill M, Marsh K, Agnew D, Ceballos L, Lanusse C, Hoerauf A, Geary J, Wanji, S, McCall J, Behan A, Ames K, Scandale I, Silber SA. Poster ASTMH Annual Meeting 2014
• Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, Terse P, Dehdashti SJ, Marugan J, Zheng W, Portilla L, Hubbs A, Pavan WJ, Heiss J, Vite CH, Walkley SU, Ory DS, Silber SA, Porter FD, Austin CP, McKew JC. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem. 2014; 14(3):330-9.
• Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Silber S, Sloan S, Leitz GJ. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. J Pediatr Gastroenterol Nutr. 2014 Apr; 58(4):510-7.
• Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, Silber S, Leitz G. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013 Dec;57(6):798-807
• Haddad I, Kierkus J, Tron E, Ulmer A, Hu P, Sloan S, Silber S, Leitz G. Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2013 Dec;57(6):798-807.
• Trapnell BC, Strausbaugh SD, Woo MS, Tong SY, Silber SA, Mulberg AE, Leitz G. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2011 Sep;10(5):350-6
• Adler LA, Orman C, Starr HL, Silber S, Palumbo J, Cooper K, Berwaerts J, Harrison DD. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011 Feb; 31(1):108-14.
• Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009 Jun; 29(3):239-47.
• Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol. 2007 Dec; 47(12).
• Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacology. 2007 Oct; 27(5):459-67.
• Sussman EJ, Goldberg S, Poll DS, MacVaugh H 3rd, Simson MB, Silber SA, Kastor JA. Surgical therapy of variant angina associated with non-obstructive coronary disease. Ann Intern Med. 1981 Jun; 94(6):771-4.
• Maroko PR, McDevitt JT, Fox MJ, Silber SA, Young MD, Beg M, Rockhold FW, Free SM, Herron JR, Gray JM, et al. Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial. Clin Ther. 1989; 11(1):94-119.
• Silber SA. Two cheers for the computer? Br Med J (Clin Res Ed). 1985 Jul 27; 291(6490):283-4.
• Costa JL, Silber SA, Murphy DL. Effects of reserpine and imipramine on vesicular serotonin uptake and storage in intact human platelets. Life Sci. 1977 Jul 15; 21(2):181-8.